GENSCRIPT BIO

GenScript Biotech rose to 16.83 HKD in morning trading (up 4.6%), supported by block trade activity, but subsequently retreated as investors took profits, closing at 16.10 HKD with minimal change. The recent momentum reflects strong commercial performance of CARVYKTI, a CAR-T cell therapy from Legend Biotech, an associate company treating blood cancers. Q4 2025 revenue reached 1.714 billion HKD, expanding 42.75% year-over-year, showing robust business growth, yet the company reported a net loss of 1.974 billion HKD, typical of early-stage biotech firms with substantial R&D spending. Regarding valuation, the stock has gained 25.88% year-to-date, trading 17% below its 52-week high of 19.4 HKD while maintaining a premium above its 60-day moving average of 13.37 HKD. While revenue growth remains strong, the company's ongoing losses warrant continued monitoring.

GenScript Biotech rose 3% today, primarily driven by positive clinical progress of CAR-T therapy LB2501 from affiliate Legend Biotech. The stock surged to 16.20 in the morning session and extended gains into the afternoon, reaching an intraday high of 16.44, reflecting optimistic market sentiment toward the clinical pipeline. Latest quarterly results show operating revenue grew 42.7% year-over-year to HK$1.715B, demonstrating strong business expansion momentum, while net loss remained at HK$1.974B with a negative net margin of -115%, typical of biotech companies in heavy investment phase. On valuation, the stock has gained 25.8% year-to-date with a market cap of HK$35.2B, but still trades 17% below the 52-week high of HK$19.40. Notably, today's turnover rate of 0.95% was relatively modest, suggesting limited institutional participation; further gains would require stronger catalysts.

GenScript Biotech surged around 7% today on a block trade, reaching an intraday high of HK$16.62 and closing at HK$15.62. The rally is underpinned by positive clinical data from associated company Legend Biotech's CAR-T therapy LB2501, which provides medium-term support to earnings outlook. Yet recent financials reveal a deep tension: Q4 2025 revenue surged 42.75% year-over-year to HK$1.71 billion and operating income swung positive, but net loss ballooned to HK$1.97 billion with a -115% net margin, underscoring the company's heavy research-funding burn phase. From a valuation standpoint, GenScript has gained 22.13% year-to-date and sits 19.48% below its 52-week high of HK$19.4, with the current price of HK$15.62 trading above both the 20-day moving average (HK$13.52) and 60-day moving average (HK$13.29), suggesting a near-term recovery posture, though questions linger about the cash-burn model's sustainability.

GenScript Biotech closed at HK$14.66 today, up 4.34% from the previous close, buoyed by strong sales of Legend Biotech's CAR-T therapy CARVYKTI, in which GenScript holds an equity stake. The morning session dipped to HK$13.77, but afternoon trading recovered sharply, peaking at HK$14.74 around 14:26 Beijing time, reflecting renewed confidence in the biotech sector. Q4 revenue reached HK$1.714 billion, a 42.75% year-over-year increase, though the company posted a net loss of HK$1.974 billion—a typical pattern for early-stage biotech firms making heavy R&D investments. Year-to-date the stock is up 14.62%, now trading well above its 60-day moving average of HK$13.263, yet remains 24.43% below the 52-week high of HK$19.4. Market appetite for next-generation immune therapies like CAR-T remains robust; however, the company's current unprofitability and dependence on pipeline success warrant close monitoring.

GenScript surged roughly 6.3% to HK$14.05 today, primarily driven by positive developments from affiliated firm Legend Biotech's CAR-T pipeline — specifically, robust CARVYKTI commercial sales and encouraging early clinical data from LB2501, which reinvigorated investor confidence in the company's cell therapy strategy. The stock rallied to an intraday high of HK$14.06 during the morning session (BJ 11:16). On the earnings front, the latest quarterly results showed revenue climbing 42.75% year-over-year to HK$17.14 billion with operating income swinging to profitability, yet the company remains deeply in the red, posting net losses of HK$19.74 billion and a net margin of negative 115%. In terms of valuation and price positioning, the stock trades 27.6% below its 52-week peak of HK$19.4, while year-to-date gains stand at just 9.85%, leaving limited recovery room. Notably, recent reports also cautioned investors to exercise prudence, tempering exuberance around these clinical advances.